US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
AU671450B2
(en)
*
|
1992-03-20 |
1996-08-29 |
Baylor College Of Medicine |
A DNA transporter system and method of use
|
DK0636028T3
(da)
*
|
1992-04-03 |
2004-07-12 |
Univ California |
Selvorganiserende polynucleotidleveringssystem omfattende et amfipatisk kationisk peptid
|
WO1994006923A1
(en)
*
|
1992-09-24 |
1994-03-31 |
The University Of Connecticut |
Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
|
AU6427994A
(en)
*
|
1993-03-19 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Process for preparing cancer vaccines
|
DE4311651A1
(de)
*
|
1993-04-08 |
1994-10-13 |
Boehringer Ingelheim Int |
Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
|
WO1995002698A1
(en)
*
|
1993-07-12 |
1995-01-26 |
Life Technologies, Inc. |
Composition and methods for transfecting eukaryotic cells
|
DE4335025A1
(de)
*
|
1993-10-14 |
1995-04-20 |
Boehringer Ingelheim Int |
Endosomolytisch wirksame Partikel
|
EP0648493A1
(en)
*
|
1993-10-19 |
1995-04-19 |
Tadatsugu Prof. Dr. Taniguchi |
A method to reverse the phenotype of transformed cells by the transcription factor IRF-1
|
US5928944A
(en)
*
|
1994-02-04 |
1999-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of adenoviral-medicated cell transfection
|
MX9603866A
(es)
*
|
1994-03-18 |
1997-03-29 |
Boehringer Ingelheim Int |
Procedimiento para el tratamiento de celulas eucarioticas.
|
WO1995026411A2
(en)
*
|
1994-03-25 |
1995-10-05 |
The Uab Research Foundation |
Composition and methods for creating syngeneic recombinant virus-producing cells
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
CA2190963A1
(en)
*
|
1994-05-30 |
1995-12-07 |
Matthew Cotten |
Method for introducing foreign matter into higher eukaryotic cells
|
DE4418965A1
(de)
*
|
1994-05-31 |
1995-12-07 |
Boehringer Ingelheim Int |
Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
|
DE4426429A1
(de)
*
|
1994-07-26 |
1996-02-01 |
Boehringer Ingelheim Int |
Verfahren zum Einführen von DNA in höhere eukaryotische Zellen
|
US6468981B1
(en)
|
1994-07-29 |
2002-10-22 |
Emory University |
Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
|
US5525606A
(en)
|
1994-08-01 |
1996-06-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
|
US5962311A
(en)
*
|
1994-09-08 |
1999-10-05 |
Genvec, Inc. |
Short-shafted adenoviral fiber and its use
|
US5965541A
(en)
*
|
1995-11-28 |
1999-10-12 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5846782A
(en)
*
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US5559099A
(en)
*
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
US6465253B1
(en)
*
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5837533A
(en)
*
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
EP0785276A4
(en)
*
|
1994-09-29 |
2002-01-09 |
Ajinomoto Kk |
MODIFICATION OF A PEPTIDE AND A PROTEIN
|
US6221959B1
(en)
|
1994-11-18 |
2001-04-24 |
Supratek Pharma, Inc. |
Polynucleotide compositions
|
US6359054B1
(en)
|
1994-11-18 |
2002-03-19 |
Supratek Pharma Inc. |
Polynucleotide compositions for intramuscular administration
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5770442A
(en)
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
US6127525A
(en)
*
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
DE69627644T2
(de)
*
|
1995-03-09 |
2004-02-19 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
|
WO1996029423A1
(en)
*
|
1995-03-20 |
1996-09-26 |
Baylor College Of Medicine |
Compositions and methods for inducing infection by retroviral vectors outside of their host range
|
DE19510344C1
(de)
*
|
1995-03-22 |
1996-11-07 |
Boehringer Ingelheim Int |
Verwendung einer Tumorvakzine
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US6051429A
(en)
*
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
EP0832269A1
(en)
*
|
1995-06-07 |
1998-04-01 |
Baylor College Of Medicine |
Nucleic acid transporters for delivery of nucleic acids into a cell
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
EP0874910A4
(en)
*
|
1995-06-07 |
1999-04-21 |
Life Technologies Inc |
ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
SI0833934T2
(sl)
|
1995-06-15 |
2013-04-30 |
Crucell Holland B.V. |
Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
|
US5908777A
(en)
*
|
1995-06-23 |
1999-06-01 |
University Of Pittsburgh |
Lipidic vector for nucleic acid delivery
|
GB9515356D0
(en)
*
|
1995-07-26 |
1995-09-20 |
Medical Res Council |
Improvements in or relating to delivery of nucleic acid
|
US5770720A
(en)
*
|
1995-08-30 |
1998-06-23 |
Barnes-Jewish Hospital |
Ubiquitin conjugating enzymes having transcriptional repressor activity
|
IL115199A
(en)
|
1995-09-07 |
2005-05-17 |
Opperbas Holding Bv |
Composition comprising a polynucleic acid molecule in a liposome and method using said composition
|
CA2279673A1
(en)
*
|
1995-12-15 |
1997-06-16 |
Enzo Therapeutics, Inc. |
Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
|
ATE333892T1
(de)
*
|
1996-02-09 |
2006-08-15 |
Pi-Wan Cheng |
Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
|
DE19605548A1
(de)
*
|
1996-02-15 |
1997-09-04 |
Boehringer Ingelheim Int |
Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
|
EP0904373A1
(en)
|
1996-03-14 |
1999-03-31 |
The Immune Response Corporation |
Targeted delivery of genes encoding interferon
|
DE19615803A1
(de)
|
1996-04-20 |
1997-10-23 |
Boehringer Ingelheim Int |
CELO-Virus
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
ATE252914T1
(de)
|
1996-08-13 |
2003-11-15 |
Chiron Corp |
Zusammensetzungen zur polynukleotidabgabe
|
DE19632532A1
(de)
*
|
1996-08-13 |
1998-02-19 |
Boehringer Ingelheim Int |
Verfahren zur Herstellung von Säugetieren mit definierten genetischen Eigenschaften
|
US5948681A
(en)
*
|
1996-08-14 |
1999-09-07 |
Children's Hospital Of Philadelphia |
Non-viral vehicles for use in gene transfer
|
CN1181422A
(zh)
*
|
1996-10-31 |
1998-05-13 |
上海市肿瘤研究所 |
与生长因子受体结合的多肽所构建的基因转移载体
|
US5965441A
(en)
*
|
1996-11-13 |
1999-10-12 |
The General Hospital Coporation |
HSV/AAV hybrid amplicon vectors
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US5980898A
(en)
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
WO1998027209A1
(en)
*
|
1996-12-18 |
1998-06-25 |
Emory University |
Polycationic oligomers
|
JP4289687B2
(ja)
*
|
1997-03-14 |
2009-07-01 |
ザ チルドレンズ ホスピタル オブ フィラデルフィア |
血友病の治療のための遺伝子治療で使用する方法と組成物
|
WO1998049198A1
(en)
*
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
US20050096288A1
(en)
*
|
1997-06-13 |
2005-05-05 |
Aragene, Inc. |
Lipoproteins as nucleic acid vectors
|
US6635623B1
(en)
|
1997-06-13 |
2003-10-21 |
Baylor College Of Medicine |
Lipoproteins as nucleic acid vectors
|
DE19726186A1
(de)
*
|
1997-06-20 |
1998-12-24 |
Boehringer Ingelheim Int |
Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
|
WO1999002192A1
(en)
*
|
1997-07-11 |
1999-01-21 |
Brandeis University |
Method of inducing apoptosis by reducing the level of thiamin
|
US6172211B1
(en)
|
1997-07-11 |
2001-01-09 |
Boehringer Ingelheim International Gmbh |
Nucleic acid encoding tag7 polypeptide
|
ATE417927T1
(de)
|
1997-07-30 |
2009-01-15 |
Univ Emory |
Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
AU8179898A
(en)
*
|
1997-08-07 |
1999-03-01 |
University Of Maryland At Baltimore |
Nucleic acid uptake and release vehicle
|
US6197332B1
(en)
*
|
1997-08-13 |
2001-03-06 |
Chiron Corporation |
Lipid-conjugated polyamide compounds and related compositions and methods thereof
|
US6706693B1
(en)
|
1997-08-13 |
2004-03-16 |
The Uab Research Foundation |
Vaccination by topical application of genetic vectors
|
US6348450B1
(en)
|
1997-08-13 |
2002-02-19 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom and uses thereof
|
US6716823B1
(en)
|
1997-08-13 |
2004-04-06 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom, and uses thereof
|
US20030045492A1
(en)
*
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
US20030125278A1
(en)
*
|
1997-08-13 |
2003-07-03 |
Tang De-Chu C. |
Immunization of animals by topical applications of a salmonella-based vector
|
US5998386A
(en)
*
|
1997-09-19 |
1999-12-07 |
Feldman; Arthur M. |
Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
|
AU9692498A
(en)
*
|
1997-10-10 |
1999-05-03 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Complex of biotinylated viral vector and ligand for targeted gene delivery
|
US6914131B1
(en)
|
1998-10-09 |
2005-07-05 |
Chiron S.R.L. |
Neisserial antigens
|
CA2308606A1
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
US6734338B1
(en)
|
1997-11-14 |
2004-05-11 |
Cedars-Sinai Medical Center |
Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies
|
US7294755B1
(en)
|
1997-11-14 |
2007-11-13 |
Cedars-Sinai Medical Center |
Genetic modification of male germ cells for generation of transgenic species and genetic therapies
|
EP1030929B1
(en)
*
|
1997-11-14 |
2009-03-18 |
Cedars-Sinai Medical Center |
Transfection and transfer of non-human male germ cells for generation of transgenic non-human mammals
|
EP0945138A1
(en)
*
|
1997-12-04 |
1999-09-29 |
Université Louis Pasteur de Strasbourg |
Transfection particles
|
JP2002500201A
(ja)
|
1998-01-05 |
2002-01-08 |
ユニバーシティ オブ ワシントン |
膜破壊剤を使用する増強された輸送
|
EP2278011A3
(en)
|
1998-01-14 |
2012-03-07 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisseria meningitidis antigens
|
WO1999055365A1
(en)
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
AU761780B2
(en)
|
1998-05-01 |
2003-06-12 |
Glaxosmithkline Biologicals Sa |
Neisseria meningitidis antigens and compositions
|
US7244714B1
(en)
*
|
1998-06-12 |
2007-07-17 |
Aradigm Corporation |
Methods of delivering aerosolized polynucleotides to the respiratory tract
|
US7091192B1
(en)
|
1998-07-01 |
2006-08-15 |
California Institute Of Technology |
Linear cyclodextrin copolymers
|
US6509323B1
(en)
|
1998-07-01 |
2003-01-21 |
California Institute Of Technology |
Linear cyclodextrin copolymers
|
US6245427B1
(en)
|
1998-07-06 |
2001-06-12 |
DüZGüNES NEJAT |
Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
US7396919B1
(en)
*
|
1998-07-17 |
2008-07-08 |
Mirus Bio Corporation |
Charge reversal of polyion complexes
|
AU8818398A
(en)
*
|
1998-08-21 |
2000-03-14 |
Felix Frey |
Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
|
AU767975B2
(en)
|
1998-09-11 |
2003-11-27 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
JP2002527066A
(ja)
|
1998-10-15 |
2002-08-27 |
カイロン コーポレイション |
転移性乳癌および結腸癌調節遺伝子
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
WO2000027795A1
(en)
|
1998-11-12 |
2000-05-18 |
Invitrogen Corporation |
Transfection reagents
|
WO2000029600A1
(en)
|
1998-11-19 |
2000-05-25 |
Georgetown University |
Systemic viral/ligand gene delivery system and gene therapy
|
US20050063950A1
(en)
*
|
1998-11-19 |
2005-03-24 |
Georgetown University |
Systemic viral/ligand gene delivery system and gene therapy
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
PT1141331E
(pt)
|
1998-12-16 |
2008-12-22 |
Novartis Vaccines & Diagnostic |
Quinase dependente de ciclina humana (hpnqalre)
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
GB9908195D0
(en)
|
1999-04-09 |
1999-06-02 |
Microbiological Res Authority |
Treatment of intracellular infection
|
DE19918446A1
(de)
*
|
1999-04-23 |
2000-11-23 |
Univ Eberhard Karls |
Verwendung von Coxsackievirus B3 zur Verbesserung der Transfektion von Zellen
|
US6514762B1
(en)
|
1999-04-23 |
2003-02-04 |
New Mexico State University Technology Transfer Corporation |
Delivery of nucleotides by electrochemical release
|
EP1228217B1
(en)
|
1999-04-30 |
2012-11-21 |
Novartis Vaccines and Diagnostics S.r.l. |
Conserved neisserial antigens
|
US20040009936A1
(en)
*
|
1999-05-03 |
2004-01-15 |
Tang De-Chu C. |
Vaccine and drug delivery by topical application of vectors and vector extracts
|
US6492169B1
(en)
*
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
US6696272B1
(en)
|
1999-06-02 |
2004-02-24 |
Hsc Research & Development Limited Partnership |
Products and methods for gaucher disease therapy
|
US20080281041A1
(en)
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
WO2000075164A1
(en)
*
|
1999-06-07 |
2000-12-14 |
Mirus Corporation |
COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
|
US8541548B2
(en)
*
|
1999-06-07 |
2013-09-24 |
Arrowhead Madison Inc. |
Compounds and methods for reversible modification of biologically active molecules
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
CA2385538C
(en)
*
|
1999-09-17 |
2007-11-06 |
Tgt Laboratories, S.A. De C.V. |
Recombinant adenoviral vectors and their utilization in the treatment of various types of hepatic, renal and pulmonary fibrosis and hypertrophic scars
|
AU784203B2
(en)
|
1999-10-29 |
2006-02-23 |
Glaxosmithkline Biologicals S.A. |
Neisserial antigenic peptides
|
AU3366901A
(en)
*
|
1999-12-30 |
2001-07-16 |
Novartis Ag |
Novel colloid synthetic vectors for gene therapy
|
WO2001051092A2
(en)
*
|
2000-01-07 |
2001-07-19 |
University Of Washington |
Enhanced transport of agents using membrane disruptive agents
|
EP2275129A3
(en)
|
2000-01-17 |
2013-11-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
JP4763210B2
(ja)
|
2000-02-28 |
2011-08-31 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
ナイセリアのタンパク質の異種発現
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
EP1157999A1
(en)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
EP1301612A2
(en)
*
|
2000-05-31 |
2003-04-16 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
JP2004501657A
(ja)
|
2000-06-28 |
2004-01-22 |
マックス−デルブルック−セントラム フュール モレクラーレ メディツィン |
トランスフェクション効率の改良方法
|
WO2002010219A1
(en)
*
|
2000-07-26 |
2002-02-07 |
Cho, Sung-Woo |
Oligolysine transducing domain, oligolysine-cargo molecule complex and uses thereof
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
CA2421864A1
(en)
*
|
2000-09-20 |
2002-03-28 |
Crucell Holland B.V. |
Transduction of dendritic cells using adenoviral vectors
|
EP1191104A1
(en)
*
|
2000-09-26 |
2002-03-27 |
Introgene B.V. |
Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
|
US7235233B2
(en)
*
|
2000-09-26 |
2007-06-26 |
Crucell Holland B.V. |
Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
|
DE10049010A1
(de)
*
|
2000-10-04 |
2002-04-18 |
Boehringer Ingelheim Int |
Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
|
MX357775B
(es)
|
2000-10-27 |
2018-07-20 |
J Craig Venter Inst Inc |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
WO2002034879A2
(en)
*
|
2000-10-27 |
2002-05-02 |
Invitrogen Corporation |
Method for introducing antisense oligonucleotides into eucaryotic cells
|
US6892140B1
(en)
*
|
2000-11-27 |
2005-05-10 |
Enteron, Inc. |
Immunogenic cancer peptides and uses thereof
|
MXPA00011713A
(es)
*
|
2000-11-28 |
2002-05-31 |
Tgt Lab S A De C V |
Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
|
US7635571B2
(en)
*
|
2000-12-07 |
2009-12-22 |
Siemens Healthcare Diagnostics Products Gmbh |
Amplified signal in binding assays
|
US6635466B2
(en)
*
|
2001-01-09 |
2003-10-21 |
University Of Iowa Research Foundation |
Adenovirus serotype 30 (Ad30)
|
AU2002240201A1
(en)
*
|
2001-02-02 |
2002-08-19 |
Yale University |
Peptides for facilitating composite receptor expression and translocation of macromolecules
|
AU2002250071B2
(en)
|
2001-02-13 |
2008-02-14 |
Government Of The United States, As Represented By The Secretary Of The Army |
Vaccine for transcutaneous immunization
|
US20020150566A1
(en)
*
|
2001-03-23 |
2002-10-17 |
Kun-Liang Guan |
Method of inhibiting cancerous cell proliferation using Ras mutants of GDP-bound conformation
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
US20020193295A1
(en)
*
|
2001-05-04 |
2002-12-19 |
Emanuel Calenoff |
Immunogenic peptides and uses thereof
|
JP2004535388A
(ja)
*
|
2001-04-30 |
2004-11-25 |
ターゲティッド ジェネティクス コーポレイション |
脂質含有薬物送達複合体およびそれらの生成方法
|
WO2002089586A1
(en)
*
|
2001-05-10 |
2002-11-14 |
St. Jude Children's Research Hospital |
Lung epithelial cell line for propagating viruses
|
US20030003074A1
(en)
*
|
2001-06-14 |
2003-01-02 |
Macromed, Inc. |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US20060159657A1
(en)
*
|
2001-06-14 |
2006-07-20 |
Macromed, Incorporated |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
KR100607612B1
(ko)
|
2001-06-20 |
2006-08-02 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
WO2003000707A2
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
GB0120022D0
(en)
|
2001-08-16 |
2001-10-10 |
Photobiotics Ltd |
Conjugate
|
EP2153843B1
(en)
|
2001-09-18 |
2012-08-15 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2003052117A2
(en)
*
|
2001-09-19 |
2003-06-26 |
Massachusetts Institute Of Technology |
Methods and products related to non-viral transfection
|
NZ585001A
(en)
|
2001-10-09 |
2011-08-26 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US7745418B2
(en)
*
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
EP1448586A4
(en)
*
|
2001-11-02 |
2006-03-01 |
Intradigm Corp |
THERAPEUTIC METHODS FOR NUCLEIC ACID DELIVERY VEHICLES
|
EP2325193A3
(en)
|
2001-11-02 |
2012-05-02 |
Insert Therapeutics, Inc. |
Methods and compositions for therapeutic use of RNA interference
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
ATE406912T1
(de)
|
2001-12-12 |
2008-09-15 |
Novartis Vaccines & Diagnostic |
Immunisierung gegen chlamydia tracheomatis
|
US20030228305A1
(en)
|
2002-01-02 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US8138383B2
(en)
*
|
2002-03-11 |
2012-03-20 |
Arrowhead Madison Inc. |
Membrane active heteropolymers
|
US8008355B2
(en)
*
|
2002-03-11 |
2011-08-30 |
Roche Madison Inc. |
Endosomolytic poly(vinyl ether) polymers
|
WO2003078576A2
(en)
*
|
2002-03-12 |
2003-09-25 |
Nitto Denko Corporation |
Vector for transfection of eukaryotic cells
|
WO2003105908A2
(en)
*
|
2002-03-15 |
2003-12-24 |
Department Of Veterans Affairs, Rehabilitation R & D Service |
Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
EP1571968A4
(en)
|
2002-04-16 |
2007-10-17 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
|
MXPA04008891A
(es)
*
|
2002-04-25 |
2004-11-26 |
Crucell Holland Bv |
Medios y metodos para la produccion de vectores de adenovirus.
|
US20040142450A1
(en)
*
|
2002-05-10 |
2004-07-22 |
Seo Sang Heui |
Lung epithelial cell line for propagating viruses
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US20050233993A1
(en)
*
|
2002-06-05 |
2005-10-20 |
Kadonaga James T |
Methods for promoting homologous recombination
|
ES2424971T3
(es)
|
2002-06-19 |
2013-10-10 |
Apeiron Biologics Ag |
Activación de ECA2 para el tratamiento de enfermedades cardíacas, pulmonares y renales e hipertensión
|
US20060003316A1
(en)
*
|
2002-07-15 |
2006-01-05 |
John Simard |
Immunogenic compositions derived from poxviruses and methods of using same
|
EP2402036B1
(en)
|
2002-09-06 |
2018-02-14 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for delivering the therapeutic agents covalently attached thereto
|
AU2003268505A1
(en)
*
|
2002-09-09 |
2004-03-29 |
University Of Tennessee Research Foundation |
Recombinatant mutants of rhabdovirus and methods of use thereof
|
BR0314236A
(pt)
|
2002-09-13 |
2005-08-09 |
Replicor Inc |
Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
|
EP2272958A1
(en)
|
2002-09-26 |
2011-01-12 |
ISIS Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
CN1711475A
(zh)
*
|
2002-10-10 |
2005-12-21 |
退伍军人事务部 |
利用已标记的、针对肿瘤特异性表位的活化淋巴细胞进行肿瘤的检测、定位和分级
|
AU2003291755A1
(en)
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20050026859A1
(en)
*
|
2002-11-12 |
2005-02-03 |
John Hilfinger |
Methods and compositions of gene delivery agents for systemic and local therapy
|
US20080026077A1
(en)
*
|
2002-11-12 |
2008-01-31 |
John Hilfinger |
Methods and compositions of gene delivery agents for systemic and local therapy
|
EP1569695B1
(en)
|
2002-11-13 |
2013-05-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
PT2336318E
(pt)
|
2002-11-13 |
2013-06-12 |
Genzyme Corp |
Modulação anti-sentido da expressão de apolipoproteína b
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
NZ541637A
(en)
|
2003-02-11 |
2008-07-31 |
Antisense Therapeutics Pty Ltd |
Modulation of insulin like growth factor I receptor
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US7217566B2
(en)
*
|
2003-03-24 |
2007-05-15 |
Invitrogen Corporation |
Attached cell lines
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
WO2004093788A2
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US20040220084A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for nucleic acid delivery
|
US20040220085A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for nucleic acid delivery
|
CA2524495A1
(en)
|
2003-06-03 |
2005-01-13 |
Eli Lilly And Company |
Modulation of survivin expression
|
US20100150968A1
(en)
*
|
2003-06-09 |
2010-06-17 |
Corixa Corporation |
Dna vectors
|
US7883720B2
(en)
*
|
2003-07-09 |
2011-02-08 |
Wisconsin Alumni Research Foundation |
Charge-dynamic polymers and delivery of anionic compounds
|
EP1648914A4
(en)
|
2003-07-31 |
2009-12-16 |
Regulus Therapeutics Inc |
OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
PE20050469A1
(es)
|
2003-09-18 |
2005-09-10 |
Lilly Co Eli |
Modulacion de la expresion de eif4e
|
PT1678194E
(pt)
|
2003-10-10 |
2013-09-30 |
Alchemia Oncology Pty Ltd |
Modulação da síntese e degradação de hialuronano no tratamento de doença
|
JP2007529199A
(ja)
|
2003-10-23 |
2007-10-25 |
イルミジェン バイオサイエンシーズ, インコーポレイテッド |
ウイルス感染に対する抵抗性に関連する遺伝子である、oas1における変異の検出
|
US8062891B2
(en)
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
US20090123468A1
(en)
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US20090208478A1
(en)
*
|
2003-10-24 |
2009-08-20 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
ES2411962T3
(es)
|
2003-10-24 |
2013-07-09 |
Gencia Corporation |
Métodos y composiciones para suministrar polinucleótidos
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
SI2161283T1
(sl)
|
2003-11-17 |
2014-10-30 |
Genentech, Inc. |
Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
|
DE602004027538D1
(de)
|
2003-12-01 |
2010-07-15 |
Life Technologies Corp |
Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
|
SG113562A1
(en)
*
|
2004-01-12 |
2005-08-29 |
Agency Science Tech & Res |
Polyalkyleneimine-graft-biodegradable polymers for delivery of bioactive agents
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US20050227940A1
(en)
*
|
2004-01-23 |
2005-10-13 |
City Of Hope |
Amplifying interfering RNA (RNAi) expression and effects
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US20050203047A1
(en)
*
|
2004-03-10 |
2005-09-15 |
Ulrich Thomann |
Delivery vectors for short interfering RNA, micro-RNA and antisense RNA
|
EP2700720A3
(en)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNASE H
|
DK1730280T3
(en)
*
|
2004-03-26 |
2019-02-04 |
Curis Inc |
RNA interference modulators for hedgehog signaling and applications thereof
|
US8268324B2
(en)
|
2004-03-29 |
2012-09-18 |
Galpharma Co., Ltd. |
Modified galectin 9 proteins and use thereof
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US8697139B2
(en)
|
2004-09-21 |
2014-04-15 |
Frank M. Phillips |
Method of intervertebral disc treatment using articular chondrocyte cells
|
EP1799825B1
(en)
|
2004-10-05 |
2011-06-29 |
The California Institute of Technology |
Aptamer regulated nucleic acids and uses thereof
|
US8563511B2
(en)
|
2004-10-06 |
2013-10-22 |
University Of Rochester |
Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
CA2595407A1
(en)
|
2005-01-20 |
2006-07-27 |
University Of Rochester |
Thioredoxin interacting protein (txnip) as regulator of vascular function
|
ES2852549T3
(es)
|
2005-02-09 |
2021-09-13 |
Sarepta Therapeutics Inc |
Composición antisentido para tratamiento de la atrofia muscular
|
JP2008531581A
(ja)
*
|
2005-02-23 |
2008-08-14 |
ユーエービー リサーチ ファウンデーション |
アルキル−グリコシドで増強されたワクチン接種
|
EP2050763A3
(en)
|
2005-03-10 |
2009-07-15 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
CA2603730A1
(en)
|
2005-03-31 |
2006-10-05 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
US8734851B2
(en)
*
|
2005-04-29 |
2014-05-27 |
Wisconsin Alumni Research Foundation |
Localized delivery of nucleic acid by polyelectrolyte assemblies
|
UA95446C2
(xx)
|
2005-05-04 |
2011-08-10 |
Іллюміджен Байосайєнсіз, Інк. |
Мутації в генах oas1$мутаци в генах oas1
|
DE102005023993A1
(de)
*
|
2005-05-20 |
2006-11-23 |
TransMIT Gesellschaft für Technologietransfer mbH |
Nicht virales Vektorsystem zum Transport von Nukleinsäure in die Lunge
|
WO2007062380A2
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
US20090068158A1
(en)
*
|
2005-12-09 |
2009-03-12 |
Medin Jeffrey A |
Thymidylate kinase mutants and uses thereof
|
US20090317802A1
(en)
*
|
2005-12-09 |
2009-12-24 |
Bhatia Sangeeta N |
Compositions and Methods to Monitor RNA Delivery to Cells
|
US20090074733A1
(en)
*
|
2005-12-09 |
2009-03-19 |
Medin Jeffrey A |
Thymidylate kinase mutants and uses thereof
|
US20070299027A1
(en)
|
2006-01-26 |
2007-12-27 |
Gene Hung |
Compositions and their uses directed to huntingtin
|
EP1984399A4
(en)
*
|
2006-02-10 |
2010-03-03 |
Univ California |
TRANSDUCIBLABLE DELIVERY OF SIRANA BY MEANS OF DSRNA BINDEDOMADE FUSIONS TO PTD / CPPS
|
JP5823663B2
(ja)
|
2006-03-03 |
2015-11-25 |
プロミス ニューロサイエンシズ インコーポレイテッド |
ミスフォールドsod1媒介疾患を処置および検出するための方法および組成物
|
US7718193B2
(en)
*
|
2006-03-16 |
2010-05-18 |
University Of Washington |
Temperature- and pH-responsive polymer compositions
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
CN101437943A
(zh)
|
2006-05-03 |
2009-05-20 |
波罗的科技发展有限公司 |
牢固结合的碱基-修饰的寡核苷酸和人工核酸酶组合的反义药剂
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
CA2659103C
(en)
*
|
2006-07-12 |
2019-05-21 |
The Regents Of The University Of California |
Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
EP2061443A4
(en)
*
|
2006-08-18 |
2013-07-24 |
Arrowhead Res Corp |
POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES
|
US8017109B2
(en)
*
|
2006-08-18 |
2011-09-13 |
Roche Madison Inc. |
Endosomolytic poly(acrylate) polymers
|
WO2008030604A2
(en)
|
2006-09-08 |
2008-03-13 |
Rhode Island Hospital |
Treatment, prevention, and reversal of alcohol-induced brain disease
|
EP2061484B1
(en)
|
2006-09-08 |
2012-11-07 |
Rhode Island Hospital |
Treatment, prevention, and reversal of alcohol-induced liver disease
|
US8158595B2
(en)
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
US20080213377A1
(en)
*
|
2006-12-08 |
2008-09-04 |
Bhatia Sangeeta N |
Delivery of Nanoparticles and/or Agents to Cells
|
WO2008086807A2
(en)
*
|
2007-01-19 |
2008-07-24 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
US8834918B2
(en)
*
|
2007-01-22 |
2014-09-16 |
Wisconsin Alumni Research Foundation |
Modified multilayered film
|
US20080176958A1
(en)
|
2007-01-24 |
2008-07-24 |
Insert Therapeutics, Inc. |
Cyclodextrin-based polymers for therapeutics delivery
|
EP2641971A1
(en)
|
2007-01-29 |
2013-09-25 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
WO2008103962A2
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
US7981688B2
(en)
|
2007-03-08 |
2011-07-19 |
University Of Washington |
Stimuli-responsive magnetic nanoparticles and related methods
|
EP2139447A2
(en)
|
2007-03-20 |
2010-01-06 |
Harold Brem |
Gm-csf cosmeceutical compositions and methods of use thereof
|
CA2584494A1
(en)
*
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
WO2008134879A1
(en)
|
2007-05-04 |
2008-11-13 |
University Health Network |
Il-12 immunotherapy for cancer
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
MX2010003465A
(es)
|
2007-10-02 |
2010-07-05 |
Amgen Inc |
Incremento de eritropoyetina utilizando acidos nucleicos que hibridan para micro-arn y precursores de los mismos.
|
WO2009049100A2
(en)
*
|
2007-10-09 |
2009-04-16 |
Wisconsin Alumni Research Foundation |
Ultrathin multilayered films for controlled release of anionic reagents
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
EP2077119A1
(de)
*
|
2007-12-21 |
2009-07-08 |
Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. |
Behandlung von Fibrosen und Lebererkrankungen
|
US8344116B2
(en)
*
|
2008-03-17 |
2013-01-01 |
Case Western Reserve University |
Polymers and complexes for delivery of nucleic acids to intracellular targets
|
WO2009114942A1
(en)
|
2008-03-20 |
2009-09-24 |
University Health Network |
Thymidylate kinase fusions and uses thereof
|
BRPI0911332A2
(pt)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
composições e uso de inibidores de epas1
|
GB2459436A
(en)
*
|
2008-04-08 |
2009-10-28 |
Henderson Morley Plc |
Vaccine adjuvant
|
US8324333B2
(en)
*
|
2008-06-05 |
2012-12-04 |
Wisconsin Alumni Research Foundation |
Anionic charge-dynamic polymers for release of cationic agents
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
EP3081648A1
(en)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
US10138485B2
(en)
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
KR101829469B1
(ko)
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Epo에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(epo) 관련된 질환의 치료
|
RU2551234C2
(ru)
|
2008-12-04 |
2015-05-20 |
КьюРНА,Инк.,US |
Лечение сиртуин 1 (sirt1)-связанных заболеваний путем ингибирования натурального антисмыслового транскрипта
|
JP5923306B2
(ja)
|
2008-12-04 |
2016-05-24 |
クルナ・インコーポレーテッド |
腫瘍抑制遺伝子に対する天然アンチセンス転写物の抑制による腫瘍抑制遺伝子関連疾患の治療
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
ES2658626T3
(es)
|
2009-02-12 |
2018-03-12 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
|
WO2010093904A2
(en)
|
2009-02-12 |
2010-08-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
EP2963116B1
(en)
|
2009-03-04 |
2020-11-11 |
CuRNA, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
|
EP2408919B1
(en)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
ES2627763T3
(es)
|
2009-03-17 |
2017-07-31 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el homólogo tipo delta 1 (dlk1) por inhibición de transcrito antisentido natural a dlk1
|
US8772238B2
(en)
|
2009-03-18 |
2014-07-08 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
EP3524275A1
(en)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Innate immune supression enables repeated delivery of long rna molecules
|
DK2424987T3
(en)
|
2009-05-01 |
2018-02-26 |
Curna Inc |
TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
JP6250930B2
(ja)
|
2009-05-06 |
2017-12-20 |
クルナ・インコーポレーテッド |
トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
JP2012527248A
(ja)
|
2009-05-22 |
2012-11-08 |
クルナ・インコーポレーテッド |
転写因子e3(tfe3)に対する天然アンチセンス転写物の阻害によるtfe3およびインスリン受容体基質2(irs2)関連疾患の処置
|
KR101704988B1
(ko)
|
2009-05-28 |
2017-02-08 |
큐알엔에이, 인크. |
항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
|
CA2765099A1
(en)
|
2009-06-10 |
2010-12-16 |
New York University |
Phosphorylated tau peptide for use in the treatment of tauopathy
|
US8426214B2
(en)
*
|
2009-06-12 |
2013-04-23 |
University Of Washington |
System and method for magnetically concentrating and detecting biomarkers
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
CA2765509C
(en)
|
2009-06-16 |
2021-08-17 |
Joseph Collard |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
KR101807323B1
(ko)
|
2009-06-24 |
2017-12-08 |
큐알엔에이, 인크. |
Tnfr2에 대한 천연 안티센스 전사체의 억제에 의한 종양 괴사 인자 수용체 2(tnfr2) 관련된 질환의 치료
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
EP2462229B1
(en)
|
2009-08-05 |
2016-05-11 |
CuRNA, Inc. |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
CA2771172C
(en)
|
2009-08-25 |
2021-11-30 |
Opko Curna, Llc |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
WO2011028950A1
(en)
|
2009-09-02 |
2011-03-10 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US20130079382A1
(en)
|
2009-10-12 |
2013-03-28 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
WO2011052804A1
(en)
*
|
2009-10-30 |
2011-05-05 |
Tokyo University Of Science Educational Foundation Administrative Organization |
Method of delivering agent into target cell
|
US20120244169A1
(en)
|
2009-11-06 |
2012-09-27 |
Fibrogen, Inc. |
Treatment for Radiation-Induced Disorders
|
US20110117668A1
(en)
*
|
2009-11-09 |
2011-05-19 |
University Of Washington Through Its Center For Commercialization |
Self-powered smart diagnostic devices
|
US9080933B2
(en)
|
2009-11-09 |
2015-07-14 |
University Of Washington Through Its Center For Commercialization |
Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
|
US20110237540A1
(en)
*
|
2009-11-23 |
2011-09-29 |
Crawford Thomas C |
Cyclodextrin-based polymers for therapeutic delivery
|
PE20121584A1
(es)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
EP2509953B1
(en)
|
2009-12-11 |
2016-03-30 |
Genecode AS |
Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
|
KR101823702B1
(ko)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료
|
RU2619185C2
(ru)
|
2009-12-23 |
2017-05-12 |
Курна, Инк. |
Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
|
CN102869776B
(zh)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
|
WO2011090740A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
US8962585B2
(en)
|
2009-12-29 |
2015-02-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
KR101878501B1
(ko)
|
2010-01-04 |
2018-08-07 |
큐알엔에이, 인크. |
인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료
|
KR101853509B1
(ko)
|
2010-01-06 |
2018-04-30 |
큐알엔에이, 인크. |
췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
|
CA2786535C
(en)
|
2010-01-11 |
2019-03-26 |
Curna, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
US8883739B2
(en)
|
2010-01-19 |
2014-11-11 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
JP5981850B2
(ja)
|
2010-01-25 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
AR080243A1
(es)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
SG183374A1
(en)
*
|
2010-02-24 |
2012-09-27 |
Arrowhead Res Corp |
Compositions for targeted delivery of sirna
|
WO2011127337A2
(en)
|
2010-04-09 |
2011-10-13 |
Opko Curna Llc |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
US8362207B2
(en)
|
2010-04-16 |
2013-01-29 |
Wake Forest University Health Sciences |
Multi-level specific targeting of cancer cells with IL-13
|
US20110294868A1
(en)
|
2010-04-29 |
2011-12-01 |
Monia Brett P |
Modulation of transthyretin expression
|
CA2798218A1
(en)
|
2010-05-03 |
2011-11-10 |
Curna, Inc. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
JP5866106B2
(ja)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
インスリンを産生し分泌する腸内分泌細胞の製造方法
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
EP2576783B1
(en)
|
2010-05-26 |
2017-11-29 |
CuRNA, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
WO2012008361A1
(ja)
|
2010-07-10 |
2012-01-19 |
財団法人北九州産業学術推進機構 |
細胞への核酸導入方法および核酸複合体
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
RU2624048C2
(ru)
|
2010-10-06 |
2017-06-30 |
Курна, Инк. |
Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
|
WO2012054723A2
(en)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
US20130210893A1
(en)
|
2010-10-27 |
2013-08-15 |
Curna, Inc. |
Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
|
WO2012061811A2
(en)
|
2010-11-05 |
2012-05-10 |
Fibrogen, Inc. |
Treatment method for lung remodeling diseases
|
CA2817712C
(en)
|
2010-11-12 |
2020-03-24 |
Georgetown University |
Immortalization of epithelial cells and methods of use
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
US20130344053A1
(en)
|
2010-12-28 |
2013-12-26 |
University Of Rochester |
Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides
|
EP2670411B1
(en)
|
2011-02-02 |
2019-04-10 |
Excaliard Pharmaceuticals, Inc. |
Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
CN103561725B
(zh)
|
2011-03-14 |
2018-08-31 |
国立大学法人北海道大学 |
用于肺递送的载体、导入剂及用途
|
EP2697244B1
(en)
|
2011-04-13 |
2017-05-17 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
RU2620980C2
(ru)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
|
JP6043347B2
(ja)
|
2011-06-16 |
2016-12-14 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
線維芽細胞増殖因子受容体4の発現のアンチセンス調節
|
US10350277B2
(en)
|
2011-09-07 |
2019-07-16 |
Icahn School Of Medicine At Mount Sinai |
Ceramidase and cell differentiation
|
CN103814132B
(zh)
|
2011-09-20 |
2018-06-05 |
苏州瑞博生物技术有限公司 |
Gcgr表达的反义调节
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
CN103906838A
(zh)
|
2011-10-25 |
2014-07-02 |
Isis制药公司 |
Gccr表达的反义调节
|
WO2013138374A2
(en)
|
2012-03-15 |
2013-09-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
CA2880869A1
(en)
|
2012-08-20 |
2014-02-27 |
The Regents Of The University Of California |
Polynucleotides having bioreversible groups
|
WO2014041179A1
(en)
|
2012-09-17 |
2014-03-20 |
Chemedest Ltd. |
Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
|
WO2014055493A1
(en)
|
2012-10-02 |
2014-04-10 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
EP2908853B1
(en)
|
2012-10-21 |
2018-12-05 |
University Of Rochester |
Thy1 (cd90) as a therapy to control adipose tissue accumulation
|
US10415024B2
(en)
|
2012-11-16 |
2019-09-17 |
Poseida Therapeutics, Inc. |
Site-specific enzymes and methods of use
|
WO2014152497A2
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
EP2992112B1
(en)
|
2013-04-22 |
2020-06-03 |
Icahn School of Medicine at Mount Sinai |
Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
|
WO2014197938A1
(en)
|
2013-06-13 |
2014-12-18 |
Antisense Therapeutics Ltd |
Combination therapy
|
TWI736514B
(zh)
|
2013-09-05 |
2021-08-21 |
美商薩羅塔治療公司 |
酸性α葡萄糖苷酶之反義股誘導之外顯子2包含
|
US10036020B2
(en)
|
2013-09-19 |
2018-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting JC virus (JCV)
|
PL3068797T3
(pl)
|
2013-11-11 |
2020-06-29 |
Wake Forest University Health Sciences |
Konstrukty wielowalentnego celowania w nowotwory
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
BR112016026581A2
(pt)
|
2014-05-14 |
2017-10-31 |
Alex Levitzki Man And Holdings Ltd |
vetores de polietilenoimina polietilenoglicol melhorados
|
EP3145550B1
(en)
*
|
2014-05-19 |
2019-03-27 |
BioNTech AG |
Particles comprising protamine and rna in combination with endosome destabilizing agents
|
WO2015200901A1
(en)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
EP3169310A1
(en)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
US11191811B2
(en)
|
2014-11-19 |
2021-12-07 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
US10849917B2
(en)
|
2015-06-01 |
2020-12-01 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type VII collagen
|
CN108026519A
(zh)
|
2015-06-17 |
2018-05-11 |
波赛达治疗公司 |
将蛋白质定向至基因组中的特定基因座的组合物和方法
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
CN108699555A
(zh)
|
2015-10-09 |
2018-10-23 |
萨勒普塔医疗公司 |
用于治疗杜兴肌营养不良和相关病症的组合物和方法
|
WO2017079442A1
(en)
|
2015-11-04 |
2017-05-11 |
Icahn School Of Medicine At Mount Sinai |
Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
|
CA3007424A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
SG11201805341RA
(en)
|
2015-12-23 |
2018-07-30 |
Univ Queensland Technology |
Nucleic acid oligomers and uses therefor
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
US11060089B2
(en)
|
2016-04-18 |
2021-07-13 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
US11246868B2
(en)
|
2016-04-26 |
2022-02-15 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
AU2017312116A1
(en)
|
2016-08-17 |
2019-03-07 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
EP3645546A4
(en)
|
2017-06-30 |
2021-12-01 |
Solstice Biologics, Ltd. |
CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE
|
WO2019055460A1
(en)
|
2017-09-13 |
2019-03-21 |
The Children's Medical Center Corporation |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRANSPOSON-ASSOCIATED DISEASES
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
WO2019126578A1
(en)
|
2017-12-20 |
2019-06-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
US20210155959A1
(en)
|
2018-04-06 |
2021-05-27 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
WO2022226291A1
(en)
|
2021-04-22 |
2022-10-27 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|